Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
This preventive drug could be a 'game changer' in ending the HIV epidemic
In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating HIV transmission during sexual contact. But its cost could be an issue.
Why Indian patients groups are opposing patent requests for blockbuster HIV drug lenacapavir
Granting patents to US firm Gilead Sciences for lenacapavir could hinder global efforts to end AIDS & restrict access to affordable generics in India, warn civil society organisations.
Patent applications for HIV prevention drug opposed in India
Indian Patent Office to hear objections against Gilead's Lenacapavir patent claims, crucial for affordable HIV treatment worldwide.
Patent opposition case against Gileadās long-acting HIV injectable drug, comes up this week
The US-based Gilead Sciencesā long-acting injectable HIV drug lenacapavir is at the centre of a patent opposition case scheduled to come up this week at the Indian Patent Office (IPO). Civil society group Sankalp Rehabilitation Trust had opposed Gileadās patent application on the grounds that it was a known compound.
GlobalData on MSN
6d
Gileadās lenacapavir: HIV prospects strongest in long-acting combos with Merckās islatravir
Gilead Sciencesā capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
gaycitynews
2d
Injectable PrEP continues to show promising results
There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...
STAT
4d
Tested in Africa, used in America
The process for translating clinical trial results into action for young women in Africa has been left to our imaginations, ...
newsbytesapp.com
4d
Meet Lenacapavir: The drug that could end HIV epidemic
Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...
9d
Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir āhas the potential to be one of the most impactful interventionsā in the battle against ...
10d
on MSN
Twice-a-year injection reduced risk of HIV infection by 96%, drug company says ā more than daily PrEP pill
A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP.
HealthDay on MSN
9d
Twice-Yearly Injection Cuts HIV Risk by 96%, But Will Cost Cut Access?
It could be a real breakthrough for people at risk for HIV infection: A shot given every six months that reduces their risk ...
10d
on MSN
Twice-yearly injection reduced HIV infections by 96 percent, company says
Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...
10d
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Gilead Sciences' Phase 3 trial results show twice-yearly HIV-1 capsid inhibitor lenacapavir reduced HIV infections by 96%, ...
infectiousdiseaseadvisor.com
4d
Twice-Yearly Injectable Lenacapavir Bests Daily PrEP Tablet for HIV Prevention
Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback